Semalytix Raises €5.7M to Advance Agentic AI Platform for Real-World Patient Insights

Semalytix has secured €5.7 million in new funding to scale its Agentic AI platform, expand its global footprint, and enhance its PatientGPT analytics technology. Led by Holland Capital with support from existing investors, the round will accelerate the company’s efforts to transform real-world patient data into actionable intelligence for top pharmaceutical companies.

Expansion of Patient-Centric AI Infrastructure
The funding will support further development of Semalytix’s data foundation, which now integrates insights from 100 million public social sources, 33 million medical publications, and over 400,000 clinical trial outcomes. This expanded dataset underpins next-generation Agentic AI models designed to help pharmaceutical teams access real-time patient experience insights across the drug development lifecycle.

Growing Commercial Momentum in Global Pharma
Semalytix has already gained traction with multiple top-20 pharma companies, reflecting rising industry demand for scalable tools capable of navigating complex, siloed real-world data. The new capital will enable the company to strengthen teams across AI, customer success, and commercial operations while accelerating international expansion in Europe and the United States.